Hamdan Bin Rashid Al Maktoum Foundation Opens Applications for 2025 Educational Awards
The Hamdan Bin Rashid Al Maktoum Foundation for Medical and Educational Sciences has officially opened applications for its 2025 Local and GCC Educational Awards.
The prestigious awards aim to recognize outstanding contributions in the education sector and foster innovation at both local and regional levels.
Dr. Khalifa Al Suwaidi, Executive Director of the foundation, highlighted the significance of these awards in advancing educational excellence. 'Honouring teachers, educators, students, and institutions enhances school performance, improves education quality, and drives sustainable development,'
he stated, encouraging innovative and leadership-driven submissions.
The foundation's local awards include the Distinguished Student Award and the Distinguished Undergraduate University Student Award, celebrating academic and extracurricular excellence. The Distinguished School Award recognizes institutions that achieve remarkable academic results while implementing innovative governance practices. The Distinguished Teacher Award honours educators who exceed traditional teaching methods, while the Distinguished Educator Award acknowledges professionals pioneering sustainable educational methodologies. Additionally, the Education Supporting Institutions Award is dedicated to government and private entities contributing significantly to UAE education.
At the GCC level, the foundation extends its awards to recognize educational innovation across the region. The Distinguished Student Award and Distinguished Teacher Award commend exceptional academic and teaching contributions, while the Distinguished Educator Award celebrates leaders enhancing educational systems. The Distinguished School Award honours institutions implementing cutting-edge academic standards.
Applications will remain open until July 15, 2025. To support candidates, the foundation will conduct workshops from February to July 2025, guiding participants through the criteria and application process. Evaluations, including interviews and virtual visits, will take place between September and October 2025. The winners will be announced and honoured at an official ceremony in 2026, celebrating their invaluable contributions to education.
News Source: Emirates News Agency
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
4 days ago
- Web Release
Hamdan Foundation Advances to Judging Stage of 2025 Medical Awards After Screening 330 Submissions
Hamdan Bin Rashid Al Maktoum Foundation for Medical and Educational Sciences has announced the completion of the screening process for the 2025 Medical Awards, which aim to recognize outstanding achievements in healthcare at both the local and regional levels. According to the awards committee, this year's cycle received a total of 330 submissions from 18 countries, including the United Arab Emirates, Saudi Arabia, Lebanon, Egypt, Oman, Iraq, India, Kuwait, the United Kingdom, Qatar, Jordan, the Democratic Republic of the Congo, Morocco, the United States, Pakistan, Tunisia, Syria, and Ghana. Following an initial review, 261 submissions advanced to the administrative and technical screening stage, which involved verifying compliance with the award's eligibility criteria and guidelines. Of those, 161 applications were confirmed as eligible and are now set to proceed to the judging phase, scheduled to begin on 2 June and continue until 15 October. The judging process will be carried out by specialized committees comprising distinguished experts in the field. Each submission will be assessed according to the specific evaluation criteria established for each award category. Dr. Salama Al Muhairi, Director of Medical Excellence at Hamdan Bin Rashid Al Maktoum Foundation, emphasized the significance of this stage, noting that the evaluation and screening of submissions adhere to the highest standards to ensure transparency and fairness throughout the process. She added that these efforts reflect the merit and credibility of the Medical Excellence Awards, which seek to spotlight innovations and achievements that contribute to the advancement of medical practices. The awards also aim to encourage and support researchers in producing impactful and innovative studies in medicine and healthcare. The Foundation is committed to sharing the benefits of award-winning work, offering it as a source of inspiration and a model for excellence in scientific and medical fields. These achievements also contribute to the development of new solutions to address growing challenges in the healthcare sector. The Medical Excellence Awards consist of two main categories. The first is dedicated to supporting health and research achievements across the Arab world and includes the Arab Award for Health Sector Research and the Arab Award for Genetic Sciences. The second category focuses on recognizing exceptional contributions within the United Arab Emirates and includes the Best Research in Healthcare Award, the Innovation in Healthcare Award, and the Hamdan Award for Distinguished Personalities. Over previous cycles, the awards have garnered wide recognition and attracted high-quality submissions from both inside and outside the UAE. This success reflects the Foundation's commitment to supporting innovation and fostering a culture of excellence in the healthcare sector, while highlighting major accomplishments in scientific research and healthcare delivery.
Arabian Business
5 days ago
- Arabian Business
Inside Insilico's bid to create the UAE's first homegrown cancer drug
Clinical-stage biotech company Insilico Medicine recently announced it will attempt to discover the first novel cancer drug developed entirely in the United Arab Emirates with just four scientists and its proprietary AI platform to complete work that traditionally takes hundreds of researchers and years of effort. The Abu Dhabi-based team aims to identify promising cancer targets, design new molecules, and prepare a complete preclinical data package within 18 months—a process that typically takes pharmaceutical companies three to five years and costs hundreds of millions of dollars. 'Our Masdar City centre already hosts around 60 AI and biotech specialists. By tasking four of them with a complete end-to-end discovery run, we aim to prove that any GCC nation equipped with cloud compute, wet-lab automation and local talent can create world-class therapeutics,' Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, told Arabian Business. The initiative represents both a scientific experiment and a geopolitical statement as it has the potential to transform the Middle East's role in global pharmaceutical development while challenging fundamental assumptions about where and how drug discovery can occur in the AI era. Four scientists, one AI The team consists of two computational chemists, one medicinal chemist, and one translational biologist – a deliberately lean operation working alongside Insilico's proprietary AI system, They are targeting what the company describes as 'medium-novelty and genetically validated synthetic-lethality targets' for solid tumours –essentially, seeking ways to kill cancer cells by exploiting specific genetic vulnerabilities. In pharmaceutical terms, the team is working at breakneck speed. Their roadmap calls for finalising a biological target by Q3 2025, generating promising molecular structures in under 30 days, and completing the entire preclinical package within 18 months. Traditional drug discovery typically takes three to five years just to reach the preclinical stage. 'Humans still design strategy and verify results, but AI handles the brute-force search, learns from every experiment in real time, and steers us away from dead ends,' explained Zhavoronkov. His description evokes a chess grandmaster working with a silicon partner—humans providing intuition and judgment, the machine crunching through billions of possibilities. Why the UAE? The choice of Abu Dhabi might seem puzzling at first. The UAE has invested heavily in healthcare infrastructure, but it remains far from established biotech hubs like Boston, San Francisco, or Cambridge. For Zhavoronkov, that's precisely the point. 'The reason we chose the UAE is because we already have a base there,' he said, referring to the AI Research and Development Centre that Insilico opened in Masdar City in 2023 with support from the Abu Dhabi Investment Office. 'UAE scientists helped discover a drug but they never tried to take full control over the drug discovery program.' This initiative – which Zhavoronkov is careful to note is self-funded by Insilico, not UAE government money – is as much about proving a concept as it is about discovering a specific drug. If a small team in Abu Dhabi can successfully identify a viable cancer treatment, it suggests that any country with sufficient computing resources and a small cadre of specialists could potentially develop life-saving medications. 'Not just lucky' Insilico's approach builds on research dating back to 2016, when the company published one of the first papers describing how generative adversarial networks (GANs) – the same AI architecture later used in image generators like DALL-E – could design novel molecules. The biotech landscape is littered with AI companies that promised to revolutionise drug discovery but delivered little. Zhavoronkov seems acutely aware of this skepticism. 'Since 2021 we have nominated 22 development candidates, advanced 10 into the clinic, completed four Phase I trials and a Phase IIa – without a single clinical failure,' he said. 'Those numbers convert skepticism into evidence.' Asked why Insilico has succeeded where others have not, Zhavoronkov pointed to four specific factors: 'Pristine, well-curated data – quantity without quality is noise; a closed experimental loop where every prediction is rapidly tested in-house and fed back to the models; deep integration of AI engineers, biologists and chemists under one roof… and many experimentally-validated AI models that we know worked in real world.' In an industry where approximately 90 per cent of drug candidates fail during development, Insilico's lead drug, Rentosertib, recently showed positive results in a Phase IIa trial for idiopathic pulmonary fibrosis (a serious lung disease that causes scarring of the lungs). The company reported that Rentosertib demonstrated favourable safety and tolerability across all dose levels, with promising early efficacy signals after just 12 weeks of treatment. In January 2025, Nature Biotechnology published a paper detailing Rentosertib's journey from AI algorithms to clinical trials – the first comprehensive account of an AI-discovered and AI-designed drug from initial concept to human testing. The company is already planning to expand across the Gulf region. Insilico recently signed a Memorandum of Understanding with Saudi Arabia's Ministry of Investment and plans to establish an operation in Riyadh by 2026, with partial funding from Aramco's Prosperity7 Ventures. The company is also in discussions with Qatar, Kuwait, Bahrain, and Oman about potential expansion. 'If the pilot hits its timelines, we will deploy identical micro-teams across the region, accelerating the sovereign drug-discovery capabilities where it matters most,' Zhavoronkov said. The bigger picture Beyond regional implications, Insilico's experiment touches on a profound question: does drug discovery still need massive teams, extensive physical infrastructure, and geographical proximity to traditional biotech clusters? 'The goal is to have multiple AI-originated drugs approved and on pharmacy shelves, with a steady stream of new candidates entering the clinic every year,' he said. '[For Insilico Medicine,] success looks like regulators, payers and physicians treating AI-designed medicines as the norm – much like jetliners are now designed in silico.' Alex Aliper, Co-Founder and President of Insilico Medicine, framed the effort in economic terms, suggesting that channelling the Gulf's 'deep technology' investments into 'life-saving medicines offers the fastest way to diversify economies and extend healthy longevity' in the region.
Khaleej Times
7 days ago
- Khaleej Times
Saal.ai and Intertec Systems announce strategic collaboration
a cognitive technology company wholly owned by Abu Dhabi Capital Group (ADCG), and a leader in Artificial Intelligence (AI) and Big Data innovation, has announced a strategic collaboration with Intertec Systems, a regionally recognized digital transformation and cybersecurity solutions provider, to jointly deliver cutting-edge AI and Big Data use cases across the Gulf Cooperation Council (GCC) region. At the core of this partnership is DigiXT – a Made-in-UAE Big Data platform developed by Designed to meet the strategic needs of governments and enterprises in the region, DigiXT empowers clients to extract actionable insights from complex and large-scale data ecosystems while retaining full data sovereignty and operational control. What makes DigiXT uniquely valuable is its flexible deployment capability—it can be implemented both on-premises and on the cloud, giving organizations the confidence to align their digital initiatives with their specific security, compliance, and performance requirements. This level of control ensures that customers benefit from a powerful, scalable, and secure data foundation without compromising on regulatory expectations. The partnership leverages deep domain expertise in AI, machine learning, and data engineering, and combines it with Intertec Systems' strong regional presence, digital & cloud capabilities, and delivery excellence. Founded in 1991, Intertec Systems brings over three decades of success across sectors including public sector, healthcare, utilities, financial services, and enterprises. Vikraman Poduval, CEO of said: 'With DigiXT, we're not just delivering technology—we're enabling digital independence for the region. Intertec's strong local credibility and execution strength make them the ideal partner to scale this impact across the GCC.' For his part, Naresh Kothari, Managing Director, Intertec Systems added: 'This partnership with is a powerful step forward in delivering regionally developed, secure, and intelligent platforms. With digiXT, we aim to help our clients transform faster, smarter, and with greater control.' This collaboration represents a shared commitment to building future-ready digital capabilities, promoting regional innovation, and advancing data-driven transformation underpinned by strategic autonomy and technological excellence.
